NLR was an independent prognostic factor for PFS in patients with hormone receptor-positive BC receiving endocrine therapy as initial treatment (HR = 3.93; 95%CI 1.4–10.84; p = 0.008) [59]. Here, NR4A1 is linked to breast cancer.